Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Fitterfly is a health technology enterprise focused on metabolic wellness, utilizing innovative, customized technology and scientific principles to assist individuals in managing conditions like diabetes, obesity, heart disease, and other metabolic issues. Their offerings, including Fitterfly Diabetes Prime and Fitterfly Weight Loss, present thorough and tailored strategies that feature real-time blood glucose monitoring through a non-invasive Continuous Glucose Monitoring (CGM) device, as well as personalized plans for diet, exercise, stress management, and sleep, all complemented by dedicated health coaches. These initiatives aim to empower individuals to reach significant health milestones with results that genuinely impact their lives. Fitterfly’s methodology is anchored in rigorous behavioral therapy, emphasizing the cultivation of healthy habits through a focus on nutrition, physical activity, stress reduction, and sleep hygiene. Their digital therapeutic solutions are clinically validated, demonstrating successful outcomes such as an average decrease of 1.96 points in HbA1c levels within three months, alongside an average weight reduction of 5 kg, showcasing the effectiveness of their programs in promoting overall health. Ultimately, Fitterfly strives to transform the way people approach their metabolic health through a blend of technology and personalized care.

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

Free
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Fitterfly

Founded

2016

Country

India

Website

www.fitterfly.com

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Product Features

Product Features

Alternatives

Alternatives

Omada Reviews

Omada

Omada Health
Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs